Womens Health Update

Guest: Ilene Galinsky BSN,MSN,ANP-C Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.

Guest: Ilene Galinsky BSN,MSN,ANP-C Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Harry Paul Erba, MD, PhD Guest: Uma Borate, MD, MS With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Host: Prathima Setty, MD Issues of vaginal health are commonly seen in post-menopausal women, breast cancer survivors and women who have had a hysterectomy. According to the US Census Bureau there are nearly 46M women between the ages of 50 and 80, and over 2.8M breast cancer survivors. Existing treatments for post-menopause vaginal health can be time intensive or messy, or contraindicated for health reasons. They also can have numerous side-effects and offer only marginal improvement -- according to a doctor associated with the study. Host Dr. Prathima Setty welcomes Dr. Mickey Karram, Director of Fellowship Program on Female Pelvic Medicine & Reconstructive Surgery at The Christ Hospital, Cincinnati, OH. Dr. Karram will share preliminary findings from a trail evaluating laser treatment on post-menopausal women and breast cancer survivors experiencing vaginal health issues. Supported by an Educational Grant from BD Diagnostics. ReachMD retains full editorial control of the content for this program.